media
Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome
Results affirm the advantages of Prota’s remission peanut OIT treatments, which lead to significant and sustained benefits including substantially improved Health Related Quality of Life
Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024
Prota Therapeutics’ CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards
Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate
First Company to Validate Significant Quality of Life Improvements Compared with Standard Care
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone:
Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients
Prota Press Release - Appointment of Patrick Machado
Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
Financing advances development of Prota’s peanut allergy remission therapy in preparation for a Phase 3 clinical trial.
Media release (prota) New data shows previously allergic children still able to tolerate peanut four years after treatment with a novel immunotherapy licensed by Prota Therapeutics
Melbourne, Australia: Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota) is pleased to announce results from a follow up study of the probiotic and peanut immunotherapy (PPOIT) treatment which it has licensed from the Murdoch Childrens Research Institute (MCRI), demonstrating long-lasting tolerance effects of treatment more than four years after the original study ended.
Researchers discover two treatments that induce peanut allergy remission in children
The research, led by the Murdoch Children’s Research Institute (MCRI), found the treatments – a combination of a probiotic together with oral immunotherapy (the gradual introduction of the allergenic food) and oral
immunotherapy alone – significantly induced remission and desensitisation.
immunotherapy alone – significantly induced remission and desensitisation.